David James Pinato
← Back to Imperial College London
Imperial College London
David James Pinato works in Cancer Immunotherapy and Biomarkers, Hepatocellular Carcinoma Treatment and Prognosis, Colorectal Cancer Treatments and Studies, Metabolism, Diabetes, and Cancer, Inflammatory Biomarkers in Disease Prognosis. Recorded institutional associations include Università degli Studi del Piemonte Orientale “Amedeo Avogadro”, Hammersmith Hospital, Imperial College London.
Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.
Selected research works
Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.
Immunotherapies for hepatocellular carcinoma
2021 · 1,816 citationsNASH limits anti-tumour surveillance in immunotherapy-treated HCC
2021 · 1,280 citationsAssociation of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer
2019 · 620 citationsA novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI)
2012 · 421 citationsThe ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma
2016 · 413 citationsPD-L1
2017 · 317 citationsPrognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score
2021 · 303 citationsIntegrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice
2020 · 272 citationsChallenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy
2020 · 248 citationsPreliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study
2022 · 235 citationsTrans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.
2021 · 224 citationsALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma
2021 · 219 citationsPersonalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept
2023 · 206 citationsImmune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease
2019 · 204 citationsImmune-based therapies for hepatocellular carcinoma
2020 · 202 citationsT-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma
2022 · 186 citationsMTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial
2020 · 182 citationsA novel and validated prognostic index in hepatocellular carcinoma: The inflammation based index (IBI)
2012 · 181 citationsClinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer
2020 · 179 citationsInternational Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma
2021 · 164 citationsClinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer
2021 · 160 citationsPrognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer
2014 · 156 citationsMatrix stiffness modulates the activity of MMP-9 and TIMP-1 in hepatic stellate cells to perpetuate fibrosis
2019 · 150 citationsDifferential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy
2021 · 150 citationsInflammation-Based Prognostic Indices in Malignant Pleural Mesothelioma
2012 · 147 citations
